Similar articles for PMID: 28373006

Year	Number of Results
2014	1
2015	3
2016	21
2017	27
2018	16
2019	4
2020	4
2021	1
2024	0

1

Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types.

Kotsakis A, Georgoulias V. Kotsakis A, et al. Lancet Oncol. 2017 May;18(5):556-557. doi: 10.1016/S1470-2045(17)30227-9. Epub 2017 Mar 31. Lancet Oncol. 2017. PMID: 28373006 No abstract available.

2

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.

Liu K, Tan S, Chai Y, Chen D, Song H, Zhang CW, Shi Y, Liu J, Tan W, Lyu J, Gao S, Yan J, Qi J, Gao GF. Liu K, et al. Cell Res. 2017 Jan;27(1):151-153. doi: 10.1038/cr.2016.102. Epub 2016 Aug 30. Cell Res. 2017. PMID: 27573173 Free PMC article. No abstract available.

3

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.

Fujii R, Friedman ER, Richards J, Tsang KY, Heery CR, Schlom J, Hodge JW. Fujii R, et al. Oncotarget. 2016 Jun 7;7(23):33498-511. doi: 10.18632/oncotarget.9256. Oncotarget. 2016. PMID: 27172898 Free PMC article.

4

Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.

Hamilton G, Rath B. Hamilton G, et al. Expert Opin Biol Ther. 2017 Apr;17(4):515-523. doi: 10.1080/14712598.2017.1294156. Epub 2017 Feb 22. Expert Opin Biol Ther. 2017. PMID: 28274143 Review.

5

Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.

Zhao C, Tella SH, Del Rivero J, Kommalapati A, Ebenuwa I, Gulley J, Strauss J, Brownell I. Zhao C, et al. J Clin Endocrinol Metab. 2018 Feb 1;103(2):365-369. doi: 10.1210/jc.2017-01905. J Clin Endocrinol Metab. 2018. PMID: 29220526 Free PMC article.

6

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Kaufman HL, et al. Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1. Lancet Oncol. 2016. PMID: 27592805 Free PMC article. Clinical Trial.

7

Avelumab: a new standard for treating metastatic Merkel cell carcinoma.

Baker M, Cordes L, Brownell I. Baker M, et al. Expert Rev Anticancer Ther. 2018 Apr;18(4):319-326. doi: 10.1080/14737140.2018.1445528. Epub 2018 Feb 28. Expert Rev Anticancer Ther. 2018. PMID: 29482384 Review.

8

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.

Tan S, Chen D, Liu K, He M, Song H, Shi Y, Liu J, Zhang CW, Qi J, Yan J, Gao S, Gao GF. Tan S, et al. Protein Cell. 2016 Dec;7(12):866-877. doi: 10.1007/s13238-016-0337-7. Epub 2016 Nov 4. Protein Cell. 2016. PMID: 27815822 Free PMC article. Review.

9

[Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].

She Y, Pan X, Xing YF, Zhou T, Zhang ZL, Shi MH, Chen YJ. She Y, et al. Zhonghua Zhong Liu Za Zhi. 2016 Dec 23;38(12):886-892. doi: 10.3760/cma.j.issn.0253-3766.2016.12.002. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998463 Chinese.

10

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.

Xu C, Zhang Y, Rolfe PA, Hernández VM, Guzman W, Kradjian G, Marelli B, Qin G, Qi J, Wang H, Yu H, Tighe R, Lo KM, English JM, Radvanyi L, Lan Y. Xu C, et al. Clin Cancer Res. 2017 Oct 1;23(19):5869-5880. doi: 10.1158/1078-0432.CCR-17-0483. Epub 2017 Jul 5. Clin Cancer Res. 2017. PMID: 28679778 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

71 results

Results by year